Insmed Incorporated

H.C Wainwright Reaffirms Buy On Insmed Following New Managment Plan For Arikayce

In a research note published today, H.C Wainwright analyst Andrew Fein reaffirmed a Buy rating on Insmed (INSM) with a $30 price target, …

Editor Ben Weinberg — August 5, 2014, 12:27 PM EDT

H.C. Wainwright Reiterates Buy On Insmed Incorporated, $30 PT

In a research note released today, H.C.

Ben Mahaney, Editor — June 18, 2014, 4:14 PM EDT

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts